biopharmadive.com· Kristin Jensen·· 3 hours agoPickScore58
Roche affirms sales outlook amid doubts about its future
In brief
Roche's third-quarter 2026 group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), beating the consensus estimate of 15.8 billion francs, but Jefferies analysts said a new ERP system boosted revenue and underlying results fell short. The company maintained guidance for mid single-digit growth for the full year.
Why it matters
The apparent beat contrasts with an analyst-flagged underlying miss, and clear biosimilar timelines for Xolair and Ocrevus help assess Roche's growth sustainability.
Source: biopharmadive.com · biopharmadive.com